Table 4.
Comparisons of median biomarker levels between survivors and non-survivors
| A | |||
|---|---|---|---|
| Total samples (n = 201) |
Survivors (n = 158) | Non-survivors (n = 43) | p-value |
| Neutrophils/mm3 | 5100 [3700; 6700] | 8400 [6050; 13600] | < 0.001 |
| IL-8 (pg/mL) | 52.82 [37.84; 83.46] | 69.12 [49.89; 104.92] | 0.043 |
| G-CSF (pg/mL) | 142.57 [122.64; 157.28] | 149.55 [130.26; 165.07] | 0.090 |
| MPO-DNA | 0.80 [0.63; 1.00] | 0.80 [0.71; 1.02] | 0.517 |
| NE-DNA | 1.04 [0.87; 1.23] | 1.05 [0.90; 1.48] | 0.439 |
| cfDNA (ng/mL) | 7.06 [4.12; 11.40] | 14.98 [7.42; 25.74] | < 0.001 |
| CitH3 (ng/mL) | 28.29 [18.10; 53.97] | 29.29 [12.34; 58.58] | 0.745 |
| 1st sample (n = 93) | Survivors (n = 74) | Non-survivors (n = 19) | p-value |
|---|---|---|---|
| Neutrophils/mm3 | 5050 [3725; 6550] | 8400 [4950; 11750] | 0.009 |
| IL-8 (pg/mL) | 42.11 [33.18; 56.48] | 61.83 [52.88; 89.06] | 0.016 |
| G-CSF (pg/mL) | 134.22 [118.12; 153.99] | 160.09 [139.92; 184.10] | 0.012 |
| MPO-DNA | 0.75 [0.63; 1.01] | 0.77 [0.71; 1.01] | 0.508 |
| NE-DNA | 1.07 [0.88; 1.19] | 1.02 [0.94; 1.57] | 0.559 |
| cfDNA (ng/mL) | 6.87 [4.01; 10.81] | 14.98 [7.73; 22.51] | 0.002 |
| CitH3 (ng/mL) | 24.51 [12.61; 34.99] | 14.80 [6.70; 29.79] | 0.129 |
| B | |||
|---|---|---|---|
| Viral phase (1–9 days) |
Survivors N =78 |
Non-survivors N =19 |
p-value |
| Neutrophils/mm3 | 4500 [3150; 6600] | 7000 [4600; 10550] | 0.011 |
| IL-8 (pg/mL) | 49.03 [34.24; 61.20] | 54.29 [42.30; 74.82] | 0.269 |
| G-CSF (pg/mL) | 136.45 [118.12; 153.91] | 155.74 [128.91; 168.02] | 0.069 |
| MPO-DNA | 0.72 [0.63; 0.95] | 0.75 [0.65; 0.90] | 0.988 |
| NE-DNA | 1.07 [0.91; 1.23] | 0.96 [0.78; 1.34] | 0.342 |
| cfDNA (ng/mL) | 6.11 [3.48; 11.45] | 7.87 [5.08; 22.21] | 0.037 |
| CitH3 (ng/mL) | 24.51 [13.76; 34.99] | 16.19 [7.76; 33.13] | 0.295 |
| Early inflammation (10 –16 days) |
Survivors N = 48 |
Non-survivors N = 11 |
p-value |
|---|---|---|---|
| Neutrophils/mm3 | 5600 [4275; 7000] | 11400 [7650; 14450] | < 0.001 |
| IL-8 (pg/mL) | 51.93 [40.97; 81.89] | 77.53 [60.24; 110.09] | 0.052 |
| G-CSF (pg/mL) | 146.64 [129.14; 159.15] | 142.57 [125.89; 175.26] | 0.731 |
| MPO-DNA | 0.85 [0.61; 1.03] | 1.61 [0.90; 2.87] | 0.026 |
| NE-DNA | 0.99 [0.86; 1.14] | 1.37 [1.10; 1.68] | 0.016 |
| cfDNA (ng/mL) | 7.11 [4.46; 9.75] | 12.59 [7.88; 26.36] | 0.008 |
| CitH3 (ng/mL) | 35.89 [21.92; 65.96] | 34.49 [17.23; 67.53] | 1.000 |
| Late inflammation (>16 days) | Survivors N = 32 |
Non-survivors N = 13 |
p-value |
|---|---|---|---|
| Neutrophils/mm3 | 5250 [4075; 6625] | 8400.00 [6500.00; 16400.00] | 0.001 |
| IL-8 (pg/mL) | 79.03 [49.63; 110.03] | 75.08 [51.72; 107.04] | 0.966 |
| G-CSF (pg/mL) | 149.55 [135.01; 156.55] | 149.42 [131.66; 161.75] | 0.920 |
| MPO-DNA | 0.87 [0.77; 1.05] | 0.78 [0.69; 1.02] | 0.466 |
| NE-DNA | 0.99 [0.88; 1.33] | 1.06 [0.90; 1.11] | 0.548 |
| cfDNA (ng/mL) | 8.35 [4.91; 12.94] | 24.62 [19.21; 39.06] | < 0.001 |
| CitH3 (ng/mL) | 54.13 [29.46; 79.69] | 73.28 [34.28; 102.09] | 0.520 |
(MPO-DNA and NE-DNA complex, cfDNA and CitH3) in all samples (n = 201)A: total samples and first sample; B: throughout the 3 evolutionary phases